心肌梗塞后的管理 右心室衰竭 右心室衰竭
Justin Haloot1, Mohamed Mahmoud1, Anand Prasad1
1Division of Cardiology, Department of Medicine, University of Texas Health San Antonio, San Antonio, Texas.
概括
在急性心肌梗塞 (MI) 后的右心室衰竭 (RVF) 是严重的. 本综述涵盖了RVF的病理生理学,管理和支持,强调了MI诱导的RVF的有限数据.
科学领域:
- 心脏病学 心脏病学
- 关键护理医学 关键护理医学
背景情况:
- 在急性心肌梗塞 (MI) 之后的右心室衰竭 (RVF) 呈现出显著的发病率和死亡率.
- 目前对MI后RVF的管理策略在很大程度上基于专家的共识和从其他RVF原因中推断出的数据.
- 对于直接与急性心脏病发作相关的RVF管理的具体临床数据非常稀缺.
研究的目的:
- 综合审查现有的关于急性心肌梗塞后的右心室衰竭的文献.
- 阐明MI诱导的RVF的病理生理学,诊断考虑和治疗干预措施.
- 讨论血液动力学监测,医疗管理和机械循环支持选项.
主要方法:
- 目前科学文章的文献综述和专家共识指南.
- 综合有关病理生理学,临床表现和管理策略的信息.
- 对血液动力学监测和机械支持干预措施的数据分析.
主要成果:
- 在急性心脏病发作中,RVF与不良结果有关,需要及时识别和干预.
- 管理依赖于一般原则,因为MI诱导的RVF的具体证据有限.
- 涉及血液动力学监测,医疗治疗和潜在的机械支持的多方面的方法至关重要.
结论:
- 有效管理MI诱导的RVF需要对其病理生理学和当前的治疗选择有充分的了解.
- 早期识别,迅速的再血管化和量身定制的血液动力学管理是关键.
- 需要进一步的研究,为这种特定患者群体建立基于证据的指导方针.
更多相关视频
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.5K
07:41Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
Published on: July 20, 2022
1.9K
相关概念视频
01:29Acute Respiratory Failure-V
126
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
126
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
01:22Heart Failure Drugs: β-Blockers
326
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
326
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K